All In Biotech

Drug Trial Radar · NCT06149286

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide in Relapsed/Refractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 580 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

580

Planned (sponsor's estimate)

Start

Dec 28, 2023

Primary completion

Apr 30, 2031

Study completion Apr 30, 2031

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Nov 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's Lymphoma (NHL). This study will be made up of two parts (Part 1 not randomized, Part 2 randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is when used in combination with lenalidomide, in participants with FL or MZL, and to determine the dose of the study drug to be used in Part 2 of this study. This combination is considered "first-in-human" as it has not been tested as a combination treatment in humans before. The aim of Part 2, of the study is to assess how well the combination of the study drug and lenalidomide works compared to the combination of rituximab (called "the comparator drug") and lenalidomide. The combination of comparator drug and lenalidomide is the current standard-of-care treatment for relapsed/refractory FL and/or MZL. Standard-of-care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug in combination with lenalidomide * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * The impact from the study drug on quality-of-life and ability to complete routine daily activities

Conditions

  • Relapsed/Refractory Follicular Lymphoma
  • Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

Interventions

  • OdronextamabDrug

    Administered per the protocol

  • LenalidomideDrug

    Administered per the protocol

  • RituximabDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs) for odronextamab in combination with lenalidomideTime frame: Up to 35 days
  2. Incidence of Treatment Emergent Adverse Events (TEAEs) for odronextamab in combination with lenalidomideTime frame: Up to 2 years
  3. Severity of TEAEs for odronextamab in combination with lenalidomideTime frame: Up to 2 years
  4. Progression-Free Survival (PFS) as assessed by Independent Central Review (ICR)Time frame: Up to 5 years

Locations

172 sites in 18 countries. Site status is shown where the registry gives one.

  • David Geffen School of Medicine at UCLA

    Los Angeles, California · Recruiting

  • Boca Raton Clinical Research (BRCR) Global

    Plantation, Florida · Recruiting

  • Indiana University and Comprehensive Cancer Center

    Indianapolis, Indiana · Recruiting

  • Hattiesburg Clinic

    Hattiesburg, Mississippi · Recruiting

  • Dartmouth Cancer Center

    Lebanon, New Hampshire · Recruiting

  • Stony Brook University Hospital

    Stony Brook, New York · Recruiting

  • Clinical Research Alliance Inc

    Westbury, New York · Withdrawn

  • East Carolina University

    Greenville, North Carolina · Recruiting

  • Prohealth Care Inc

    Waukesha, Wisconsin · Recruiting

  • Liverpool Hospital

    Liverpool, New South Wales, Australia · Recruiting

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia · Recruiting

  • Pindara Private Hospital

    Benowa, Queensland, Australia · Recruiting

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia · Recruiting

  • Epworth Freemasons

    East Melbourne, Victoria, Australia · Recruiting

  • Medical University Vienna

    Vienna, Austria · Recruiting

  • Klinikum Wels-Grieskirchen

    Wels, Austria · Recruiting

  • Ordensklinikum Linz

    Linz, Osterreich, Austria · Recruiting

  • Kepler University Hospital

    Linz, Upper Austria, Austria · Recruiting

  • Ziekenhuis Netwerk Antwerpen Stuivenberg

    Antwerp, Belgium · Recruiting

  • Institut Jules Bordet

    Brussels, Belgium · Recruiting

  • Centre Hospitalier Universitaire at Universite Catholique de Louvain Namur

    Yvoir, Namur, Belgium · Recruiting

  • Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • Algemeen Ziekenhuis AZ Delta

    Roeselare, West-Vlaanderen, Belgium · Recruiting

  • Instituto Nacional de Cancer Jose Alencar Gomes da Silva

    Rio de Janeiro, Brazil · Recruiting

  • Hospital Sirio Libanes

    São Paulo, Brazil · Recruiting

  • A Beneficencia Portuguesa de Sao Paulo, Oncology House

    São Paulo, Brazil · Recruiting

  • Hospital Sao Rafael

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Hospital Sirio Libanes Brasilia

    Brasília, Federal District, Brazil · Recruiting

  • Uopeccan Hospital do Cancer de Cascavel

    Cascavel, Paraná, Brazil · Recruiting

  • Hospital Erasto Gaertner

    Curitiba, Paraná, Brazil · Recruiting

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Centro Gaucho Integrado

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Amaral Carvalho Hospital

    Jaú, São Paulo, Brazil · Recruiting

  • Fakultni Nemocnice Brno

    Brno, Czechia · Recruiting

  • University Hospital Kralovske Vinohrady

    Prague, Czechia · Recruiting

  • Vseobecna Fakultni Nemocnice V Praze

    Prague, Czechia · Recruiting

  • University Hospital Hradec Kralove

    Hradec Králové, East Bohemia, Czechia · Recruiting

  • Centre Hospitalier d'Avignon

    Avignon, France · Recruiting

  • Centre Hospitalier Universitaire (CHU) Montpellier

    Montpellier, France · Recruiting

  • Hopital Saint Louis

    Paris, France · Recruiting

Showing 40 of 172 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.